NCT01527630 - Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2002

Primary Completion Date

January 8, 2003

Study Completion Date

January 8, 2003

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 50

A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days

Trial Locations (1)

Novo Nordisk Investigational Site, Tokyo